The regulatory milestone, identified under clearance number K253390, marks a shift from conventional composite indexing toward granular, event-level diagnostics. By leveraging deep learning algorithms, SOMNUM V3.0 identifies subtle physiological markers that often escape manual scoring. Validation data submitted during the review process demonstrated an Overall Percent Agreement exceeding 97% across all respiratory event categories, confirming the system's precision in clinical settings.

Sean Ha, President of HoneyNaps USA, noted that the clearance serves as formal validation of the company's algorithm performance. Beyond current diagnostic capabilities, the firm is actively building out next-generation digital biomarkers such as Hypoxic, Arousal, and Ventilatory Burdens. These metrics are intended to provide a more comprehensive risk profile for patients, with the company confirming plans to seek further FDA clearances to integrate these advanced features into future iterations of the software suite.